Suppr超能文献

肾移植前对HLA致敏患者进行血浆置换。

Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation.

作者信息

Alarabi A, Backman U, Wikström B, Sjöberg O, Tufveson G

机构信息

Department of Internal Medicine, University Hospital, Uppsala, Sweden.

出版信息

Int J Artif Organs. 1997 Jan;20(1):51-6.

PMID:9062832
Abstract

Immunosensitization against the human lymphocyte antigen (HLA) is a problem in most transplant centers. It prolongs the waiting list time in addition to risk of frequent acute rejections. To avoid these problems, various pretransplantation approaches have been attempted e.g. plasmapheresis (PP). The present retrospective study reports our experience with PP in this respect over a 5 year period. Twenty-three chronic hemodialysis patients with circulating panel reactive antibodies (> or = 50%) and previous kidney graft rejections were treated with 12 PP each. In addition to this, immunosuppression with cyclophosphamide and prednisolone were administered on the first day of PP and after tapering continued until transplantation. HLA-antibodies, as measured by the panel reactive antibodies and the antibody titer, decreased from about 70% to 30% (p < 0.001) and 5 steps of titerdilution, respectively with PP and immunosuppressive drugs; Twenty-two patients were transplanted with cadaveric grafts. Eight grafts were lost due to irreversible rejection, and one due to the patient's death 2 months after transplantation. The cumulative five-year graft survival at the time of follow-up was 59%. Adequate kidney function (serum creatinine mean 150 mumol/l) was observed in all grafts (n = 3) still functioning 60 months posttransplant. We conclude that pretransplantation plasmapheresis together with immunosuppressive drugs (cyclophosphamide and prednisolone) is useful in the removal of HLA antibodies in immunized patients awaiting kidney transplantation. It can be considered a valuable approach to increase the chances of successful transplantations.

摘要

针对人类淋巴细胞抗原(HLA)的免疫致敏是大多数移植中心面临的一个问题。除了频繁发生急性排斥反应的风险外,它还延长了等待名单的时间。为避免这些问题,人们尝试了各种移植前方法,例如血浆置换(PP)。本回顾性研究报告了我们在这方面5年期间血浆置换的经验。23例循环抗体反应阳性(≥50%)且既往有肾移植排斥反应的慢性血液透析患者,每人接受了12次血浆置换治疗。除此之外,在血浆置换的第一天给予环磷酰胺和泼尼松龙进行免疫抑制,在逐渐减量后持续至移植。通过群体反应性抗体和抗体滴度测量的HLA抗体,分别通过血浆置换和免疫抑制药物从约70%降至30%(p<0.001)和滴度稀释5个步骤;22例患者接受了尸体肾移植。8个移植物因不可逆排斥反应丢失,1个因患者在移植后2个月死亡而丢失。随访时累积5年移植物存活率为59%。在移植后60个月仍有功能的所有移植物(n = 3)中均观察到足够的肾功能(血清肌酐平均150μmol/l)。我们得出结论,移植前血浆置换联合免疫抑制药物(环磷酰胺和泼尼松龙)对于清除等待肾移植的免疫患者体内的HLA抗体是有用的。它可被视为增加成功移植机会的一种有价值的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验